Administration of a gonadotropin-releasing hormone agonist during pregnancy: follow-up of 28 pregnancies exposed to triptoreline
other
OA: closed
public-domain-us
Abstract
OBJECTIVE: To evaluate the teratogenic or fetal risk of a long-acting GnRH agonist (GnRH-a) triptoreline acetate (Decapeptyl; Ipsen-Biotech, Inc., Paris, France), inadvertently administrated in the first weeks of pregnancy.
DESIGN: Prospective follow-up of exposed pregnancies and case reports.
SETTING: Teratology information service of a public hospital and pharmacovigilance department of the firm.
PATIENTS: Inadvertent pregnant women receiving a treatment, mainly for endometriosis or IVF.
INTERVENTIONS: Case by case, individual estimations of the risks have been provided.
MAIN OUTCOME MEASURE: Each pregnancy issue has been analyzed.
RESULTS: No teratogenic or fetal toxic effect has been noted.
CONCLUSION: No specific hazard has been observed among newborns after inadvertent exposures to a GnRH-a during the first 20 weeks of pregnancy.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-20T06:14:21.026120+00:00
- pubmed
- last seen: 2026-05-13T22:11:13.665691+00:00
- unpaywall
- last seen: 2026-08-20T06:30:07.000247+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine